NAD+ and glutathione get sold side by side on IV drip menus as if they were interchangeable youth boosters. They are not the same molecule, they do not do the same job, and the human evidence behind injecting either of them is thinner than the menu implies.
Longevity
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
NAD+, nicotinamide adenine dinucleotide, is a coenzyme. That word matters: NAD+ does not act alone the way a hormone or a drug does. It works by pairing with enzymes and either accepting or donating electrons during metabolic reactions, then cycling back to do it again. A review of NAD+ metabolism in aging describes this dual identity clearly: NAD+ is both a redox cofactor central to energy metabolism and a consumed substrate for enzymes including sirtuins and PARPs, the DNA repair machinery that uses up NAD+ molecules rather than just borrowing them.1
Glutathione is a different kind of molecule doing a different kind of job. It is a small tripeptide built from three amino acids, and its central feature is a reactive sulfur-containing thiol group. That thiol group is what makes glutathione the cell's principal endogenous antioxidant: it neutralises reactive oxygen species and other electrophiles directly, and it also participates in detoxification reactions in the liver. A comprehensive review of glutathione's protective roles, measurement methods, and biosynthesis pathways lays out just how central this one molecule is to redox balance and xenobiotic clearance across essentially every human tissue.2
The overlap between the two is real but narrower than the marketing suggests. Both matter for how a cell handles oxidative and metabolic stress. Neither is a hormone, a vitamin in the classic sense, or a direct energy source. Past that, the mechanisms diverge: NAD+ is consumed in reactions that regulate metabolism and DNA repair, while glutathione is consumed in reactions that neutralise oxidative damage and clear certain toxins. Selling them on the same drip menu as interchangeable 'antioxidant boosts' collapses a distinction the biochemistry does not support.
Laid out next to each other, the differences are more informative than the similarities.
| NAD+ | Glutathione | |
|---|---|---|
| What it is | A coenzyme, a dinucleotide built from nicotinamide and adenine | A tripeptide antioxidant built from three amino acids |
| Primary role | Electron carrier in redox reactions; consumed substrate for sirtuins and DNA-repair enzymes1 | The cell's main endogenous thiol antioxidant and a detoxification cofactor2 |
| Where it acts | Inside essentially every cell, central to mitochondrial energy metabolism | Inside essentially every cell, with a major concentration and role in the liver2 |
| What declines with age | Tissue NAD+ levels, measured directly in humans1 | Glutathione synthesis rate, shown deficient in older adults3 |
| Best human evidence | Levels measured in human tissue across age; oral precursor trials exist but are outside this article's scope | Synthesis deficit corrected with dietary cysteine and glycine in a controlled human study3 |
| Injectable evidence | An 11-person, 6-hour IV pharmacokinetic pilot, not a clinical outcomes trial4 | A phase IIb intranasal trial in Parkinson's disease that did not establish clinical superiority5 |
| What it is NOT | Not a hormone, not an energy source you burn directly, not proven as an IV anti-aging treatment | Not a proven skin-lightening agent by IV or otherwise, a claim dermatology literature calls a myth6 |
This is where the wellness-menu pitch is not simply making things up. NAD+ levels have been measured directly in human tissue and decline with age, a finding summarised in the broader review of NAD+ metabolism during aging.1 That is a real, measured, biological fact, not a marketing invention.
The glutathione side has an equally real, and considerably more useful, finding attached to it. A controlled study in older adults found that glutathione synthesis is deficient with age, and that this deficiency is associated with oxidative stress markers. The same study found that supplementing the dietary building blocks of glutathione, the amino acids cysteine and glycine, corrected the synthesis defect.3 That is a genuinely interesting and under-quoted result: it points toward a dietary or oral intervention that restores the body's own glutathione production, rather than toward bypassing production altogether with an infusion of the finished molecule.
Put those two findings together and a pattern emerges. The decline itself is well documented for both molecules. What is far less documented is that injecting either molecule directly is the correct or even a tested way to respond to that decline.
The pilot study most often cited in support of IV NAD+ enrolled 11 people and infused NAD+ intravenously over 6 hours, then tracked how the plasma and urine NAD+ metabolome changed during and after the infusion.4 This is pharmacokinetic work: it asks where the infused NAD+ goes and how the body processes it, not whether receiving it produces any measurable clinical benefit.
There was no placebo control group, no symptom or performance endpoint, and no follow-up period long enough to say anything about durable effect. That is not a criticism of the researchers, whose stated goal was narrower and more modest than the marketing that later cited it. It is a description of what a pilot pharmacokinetic study in 11 people can and cannot tell you. It cannot tell you that a 2-hour NAD+ drip improves energy, cognition, or aging biomarkers, because it was not built to ask that question.
Astra offers compounded NAD+ injection. Being precise about what this single pilot study does and does not show is more useful to a patient deciding whether to try it than repeating the marketing claim that IV NAD+ has been 'proven' to reverse cellular aging. It has not been proven to do that, in this study or any other controlled human trial we are aware of.
The strongest controlled trial of glutathione delivered outside the normal oral route is a phase IIb study of intranasal glutathione in Parkinson's disease.5 This was a real randomized, controlled trial, considerably more rigorous in design than most of what circulates in wellness marketing, and it is worth taking seriously precisely because of that rigor. The result: the study did not establish clinical superiority for intranasal glutathione over placebo on its primary measures.
That is an important negative. A well-designed controlled trial, in a condition where oxidative stress is mechanistically plausible as a contributor, tested a non-oral delivery route for glutathione and did not find a clear clinical benefit. It does not rule out any possible use of glutathione delivered outside the gut, but it is the best piece of controlled evidence available, and it points toward caution rather than confidence.
The IV and injectable glutathione market rests on a separate and even weaker foundation: skin lightening. A dermatology literature review examining the evidence behind glutathione for skin lightening, including injectable use, concluded that the practice is closer to a persistent myth than an evidence-based treatment, citing a lack of quality controlled trials, unclear dosing, and real safety concerns with unsupervised injectable use.6 That paper's title asks the question directly: myth or verity? Its answer leans toward myth.
Astra offers compounded glutathione. We are not going to describe the injectable evidence as settled science when a targeted dermatology review has already made the opposite case, and when the strongest randomized trial of a non-oral glutathione route came back negative on its primary endpoint.
NAD+ and glutathione are not competing brands of the same drip. They are different molecules with different jobs, and neither one has injectable human evidence that matches the confidence of the marketing.
Astra Editorial, reviewing the NAD+ and glutathione literature
No. NAD+ is a coenzyme involved in redox reactions and consumed by DNA-repair and metabolic enzymes. Glutathione is a tripeptide antioxidant that directly neutralises reactive oxygen species and supports liver detoxification. They are structurally and functionally different molecules.12
Yes, both have documented age-related decline. NAD+ has been measured directly in human tissue across age.1 Glutathione synthesis has been shown to be deficient in older adults in a controlled study.3
The IV evidence for both is thin. The main human NAD+ IV data is an 11-person, 6-hour pharmacokinetic pilot with no placebo group or clinical endpoint.4 The best controlled glutathione trial used an intranasal route in Parkinson's disease and did not establish clinical superiority over placebo.5
A dermatology literature review examining this question concluded the practice functions more as a persistent myth than an evidence-based treatment, citing weak trial quality and unclear safety data for injectable use.6
For glutathione, yes: a controlled study found that dietary cysteine and glycine supplementation corrected a measured age-related glutathione synthesis deficit, without an infusion.3
Astra offers compounded NAD+ injection and compounded glutathione. This article states plainly that the injectable evidence for both is thin, including where that costs us commercially.
That is a conversation for a prescriber who can review your history. This article is educational and does not make an individual treatment recommendation.
Astra offers compounded glutathione, prescribed after an intake with a licensed clinician through a state-licensed US compounding pharmacy. This article has been direct about how thin the injectable evidence base is for both glutathione and NAD+. Read it, then decide with your prescriber whether either fits your situation.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.